LONDON, UK / ACCESSWIRE / January 02, 2018 / Active-Investors.com has just released a free research report on GW Pharma PLC (NASDAQ: GWPH). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=GWPH as the Company's latest news hit the wire. On December 28, 2017, the Company declared that the US Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for Epidiolex® (cannabidiol), an investigational treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome. The PDUFA (Prescription Drug User Fee Act) goal date for completion of the FDA review of the Epidiolex NDA is June 27, 2018. Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, GW Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=GWPH
The Company announced results from completed Phase-3 trials of Epidiolex® in LGS and Dravet syndrome along with other supportive data in November 2017.
GW Completed Rolling NDA to FDA for Epidiolex® in October
On October 30, 2017, the Company, along with its US subsidiary Greenwich Biosciences, completed the rolling submission of an NDA to FDA for Epidiolex® as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. GW Pharma had received Rare Pediatric Disease and Orphan Drug Designations from the FDA for Epidiolex® in the treatment of both LGS and Dravet syndrome.
FDA Granted Orphan Drug Designation to Zogenix's ZX008 for LGS Treatment
In March 2017, European Commission (EC) designated Zogenix, Inc.'s ZX008 (fenfluramine) as an orphan medicinal product for the treatment of LGS. In June 2017, FDA also granted ZX008 orphan drug designation for the treatment of LGS.
About Lennox-Gastaut Syndrome and Dravet Syndrome
Lennox-Gastaut syndrome (LGS), or childhood epileptic encephalopathy, is a pediatric epilepsy syndrome characterized by multiple seizure types, including mental retardation or regression, and abnormal findings on electroencephalography. Neurologic and neuropsychologic deficits inevitably appear during the evolution of LGS. The onset of LGS typically occurs between ages of three to five years.
Dravet syndrome, also known as severe myoclonic epilepsy of infancy, is a type of epilepsy with seizures that are often triggered by hot temperatures or fever. It is treated with anticonvulsant medications. It often begins around six months of age. Initial seizures are often body temperature related, severe, and long-lasting. Over time, patients with Dravet syndrome often develop multiple types of seizures, including tonic-clonic, myoclonic, and atypical absences. and are prone to bouts of prolonged seizures.
About Epidiolex® (cannabidiol)
Epidiolex® is GW Pharma's lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol. GW Pharma's Epidiolex® development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex, and Infantile Spasms.
About GW Pharmaceuticals PLC
Founded in 1998, GW Pharma is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company evaluates Epidiolex in additional epilepsy conditions and currently has ongoing clinical trials in Tuberous Sclerosis Complex and Infantile Spasms. Headquartered in Cambridge, United Kingdom, GW Pharma also has operations in the United States.
Stock Performance Snapshot
December 29, 2018 - At Friday's closing bell, GW Pharma's stock dropped 2.18%, ending the trading session at $132.01.
Volume traded for the day: 262.70 thousand shares.
Stock performance in the last month – up 9.49%; previous three-month period – up 30.07%; past twelve-month period – up 18.47%; and year-to-date - up 18.13%
After last Friday's close, GW Pharma's market cap was at $3.42 billion.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
